Download PDF
Am J Perinatol 2007; 24(3): 183-189
DOI: 10.1055/s-2007-970080
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Response to Bacillus Calmette-Guérin Vaccine in Full-Term and Preterm Infants

Lidia Negrete-Esqueda1 , Arturo Vargas-Origel1
  • 1Hospital de Gineco-Obstetricia y Pediatría, Instituto Mexicano del Seguro Social, León Gto., México
Further Information

Publication History

Publication Date:
19 March 2007 (online)

    Permissions and Reprints

ABSTRACT

The purpose of this study was to compare the delayed response to Bacillus Calmette-Guérin (BCG) immunization in preterm infants 31.4 to 34.6 weeks of age with full-terms infants by tuberculin test (tuberculin skin test with purified protein derivative [PPD]). One hundred newborns were studied from November 2000 to April 2002, consecutively allocated by convenience in two groups. Group I (GI) included 50 preterm infants from 30 to 34.2 weeks of age at inclusion and 31.4 to 34.6 weeks of age at vaccination. Group II (GII) included 50 full-term newborns. Sick or malnourished patients and those with severe malformations were not included. Newborns were evaluated at 4, 8, and 12 weeks after BCG application for scar measurement. Sixteen weeks after BCG, the PPD with Tubersol was performed. It was defined as a positive reaction when the scar diameter was of 5 mm or more; the same criterion was used for PPD response. Forty-two patients from each group concluded the study. The percentage of positive scar (GI, 64%; GII, 80%; p = 0.142) and the mean of scar diameter (4.5 and 5 mm, respectively) were not statistically significantly different. The rate of positive PPD in GI (81%) and GII (86%), and the mean of PPD in GI (6.7 mm) and GII (6.8 mm) were not statistically different (p = 0.74). Complications were not observed. This trial showed similar response to PPD after BCG vaccination in preterm and full-term infants.

KEYWORDS

BCG - preterm infants - purified protein derivative (PPD) response

REFERENCES

  • 1 Enserink M. Driving a stake into resurgent Tb. In: Vaccines and immunity news.  Science. 2001;  293 234-235
    CrossrefPubMedGoogle Scholar
  • 2 Raviglione M C, Snider D E, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.  JAMA. 1995;  273 220-226
    CrossrefPubMedGoogle Scholar
  • 3 World Health Organization .BCG Vaccine. Immunization, Vaccines and Biologicals. Available at: http://www.who.int/vaccines/en/tuberculosis2.shtml Accessed April 22, 2004
    Google Scholar
  • 4 Instituto Nacional de Estastica Geografía e Informatica .Dirección General de Información y Evaluación del Desempeño. Mexico DF; Instituto Nacional de Estadistica Geografía e Informatica 2003
    Google Scholar
  • 5 World Health Organization .Global Tuberculosis Control. The Americas. WHO Report. Geneva, Switzerland; World Health Organization 2004
    Google Scholar
  • 6 Cohn D L. Use of the Bacillus Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine.  Am J Med Sci. 1997;  313 372-376
    CrossrefPubMedGoogle Scholar
  • 7 Young D B, Robertson B D. TB vaccines: global solutions for global problems.  Science. 1999;  284 1479-1480
    CrossrefPubMedGoogle Scholar
  • 8 Horwitz M A. New recombinant BCG vaccines provide greater immunity for tuberculosis.  Proc Natl Acad Sci USA. 2000;  97 13853-13858
    CrossrefPubMedGoogle Scholar
  • 9 Doherty T M. Oral subunit vaccine and adjuvant protects against experimental TB infection.  Infect Immun. 2002;  70 3111-3121
    CrossrefPubMedGoogle Scholar
  • 10 Ramos B R, Villalobos V H, Macías Parra M. Vacuna contra la tuberculosis. In: Macías-Parra M Temas de Pediatría: Inmunizaciones. Asoc Mex de Pediatría A. C. México. Mexico DF; Editorial Interamericana, McGraw-Hill 1995: 39-52
    Google Scholar
  • 11 Chatwal J, Verma M, Thaper N, Aneja R. Waning of post-vaccinal allergy afterneonatal BCG vaccination.  Indian Pediatr. 1994;  31 1529-1533
    PubMedGoogle Scholar
  • 12 López-Antuñano F J. Usos y efectos del bacilo de Mycobacterium bovis Calmette Guerin (Vacunación con BCG).  Salud Publica Mex. 1997;  39 156-161
    PubMedGoogle Scholar
  • 13 Sirinavin S, Chotpitayasunondh T, Suwanjutha S, Sunalom P, Chantarojanasiri T. Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis.  Pediatr Infect Dis J. 1991;  10 359-365
    PubMedGoogle Scholar
  • 14 Ormerod L P, Garnett J M. Tuberculin skin reactivity four years after neonatal BCG vaccination.  Arch Dis Child. 1992;  67 530-531
    PubMedGoogle Scholar
  • 15 Kelly P, McKeown D, Clancy L. Neonatal BCG vaccination in Ireland: evidence of its efficacy in the prevention of childhood tuberculosis.  Eur Respir J. 1997;  10 619-623
    PubMedGoogle Scholar
  • 16 Houston S, Fanning A, Soskolne C L, Fraser N. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis.  Am J Epidemiol. 1990;  31 340-348
    PubMedGoogle Scholar
  • 17 Colditz G A, Berkey C S, Mosteller F et al.. The efficacy of bacillus Calmette- Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.  Pediatrics. 1995;  96 29-35
    PubMedGoogle Scholar
  • 18 Brewer T F. Preventing Tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analyses of the literature.  Clin Infect Dis. 2000;  31(Suppl 3) S64-S67
    CrossrefPubMedGoogle Scholar
  • 19 Smith S, Jacobs R F, Wilson C B. Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity.  J Pediatr. 1997;  131 16-26
    PubMedGoogle Scholar
  • 20 Dannenberg Jr A M. Fisiopatología aspectos básicos. In: Schlossberg D Tuberculosis e Infecciones por Micobacterias no Tuberculosas. 4th ed. México DF; McGraw-Hill Interamericana 2000: 19-54
    Google Scholar
  • 21 Chadha V K. Tuberculin test.  Indian J Pediatr. 2001;  68 53-58
    PubMedGoogle Scholar
  • 22 Commitee on Infectious Diseases. Screening for tuberculosis in infants and children.  Pediatrics. 1994;  93 131-134
    PubMedGoogle Scholar
  • 23 Steele R W. A new look at TB skin testing in children. Presented at the American Academy of Pediatrics, Annual Meeting October 9-13, 1991 Washington, DC;
    Google Scholar
  • 24 Al-Kassimi F A, Al-Hajjaj M S, Al-Oraney I O, Bamgboye E A. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?.  Am J Respir Crit Care Med. 1995;  152 1575-1578
    PubMedGoogle Scholar
  • 25 Uyan A P, Baskin E, Büyükbese E, Gökalp A S. Evaluating Bacillus Calmette-Guérin vaccination by tuberculin skin test response.  Indian Pediatr. 2000;  37 1106-1110
    PubMedGoogle Scholar
  • 26 Jacob T J. Immunization dialogue. BCG vaccination: some practical dilemmas.  Indian Pediatr. 1999;  36 941-944
    PubMedGoogle Scholar
  • 27 Jacob T J. BCG vaccination.  Indian Pediatr. 2000;  37 332-333
    PubMedGoogle Scholar
  • 28 Santiago E M, Lawson E, Gillenwater K et al.. A prospective study of Bacillus Calmette-Guérin scar formation and tuberculin skin test reactivity in infants in Lima, Peru.  Pediatrics. 2003;  112 e298-e302
    CrossrefPubMedGoogle Scholar
  • 29 Kröger L, Katila M L, Korppi M, Brander E, Pietikäinen M. Rapid decrease in tuberculin skin test reactivity at preschool age after newborn vaccination.  Acta Paediatr. 1992;  81 678-681
    PubMedGoogle Scholar
  • 30 Grindulis H, Baynham M ID, Scott P H, Thompson R A, Wharton B A. Tuberculin response two years after BCG vaccination at birth.  Arch Dis Child. 1984;  59 614-619
    PubMedGoogle Scholar
  • 31 Sepúlveda R L, Ferrer X, Latrach C, Sorensen R U. The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults.  Am Rev Respir Dis. 1990;  142 24-28
    PubMedGoogle Scholar
  • 32 Fine P E. Variation in protection by BCG: implications of and for heterologous immunity.  Lancet. 1995;  346 1339-1345
    CrossrefPubMedGoogle Scholar
  • 33 Agarwal A, Dutta A K. Timing and dose of BCG vaccination in infants as assessed by post-vaccination tuberculin sensitivity.  Indian Pediatr. 1995;  32 635-639
    PubMedGoogle Scholar
  • 34 Dawodu A H. Tuberculin conversion following BCG vaccination in preterm infants.  Acta Paediatr Scand. 1985;  74 564-567
    PubMedGoogle Scholar
  • 35 Sedaghatian M R, Kardouni K. Tuberculin response in preterm infants after BCG vaccination at birth.  Arch Dis Child. 1993;  69 309-311
    PubMedGoogle Scholar
  • 36 Sedaghatian M R, Hashem F, Moshaddeque Hossain M. Bacille Calmette-Guérin vaccination in pre-term infants.  Int J Tuberc Lung Dis. 1998;  2 679-682
    PubMedGoogle Scholar
  • 37 Thayyil-Sudhan S, Singh M, Paul V K, Deorari A K, Kumar A. Safety and effectiveness of BCG vaccination in preterm babies.  Arch Dis Child. 1999;  81 64F-66F
    PubMedGoogle Scholar
  • 38 Norma Oficial Mexicana NOM-031-SSA2 .1999 Para la atención a la salud del niño. Mexico DF; Secretaría de Salud, Diario Oficial de la Federación Mexico June 9, 2000
    Google Scholar
  • 39 Benavides-Vázquez L. Inmunizaciones. In: Macías-Parra M Temas de Pediatría Inmunizaciones. Asoc Mex de Pediatría A. C. México; Ed Interamericana McGraw-Hill 1995: 1-4
    Google Scholar
  • 40 Conway S P. Opportunistic immunization in hospital.  Arch Dis Child. 1999;  81 422-425
    PubMedGoogle Scholar
  • 41 Capurro H, Konichezky S A, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosis of gestational age in the newborn infant.  J Pediatr. 78;  93 120
    PubMedGoogle Scholar
  • 42 Lubchenco L O, Hansman C, Boyd E. Intrauterine growth in length and head circunference as estimated from live births at gestational age from 26 to 42 weeks.  Pediatrics. 1966;  37 403-408
    PubMedGoogle Scholar
  • 43 Bouros D, Seros G, Panaretos C H, Charalambos V, Siafakas N. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux Test).  Chest. 1991;  99 416-419
    PubMedGoogle Scholar
  • 44 Glantz S A. Primer of Biostatistics. 4th ed. New York; McGraw-Hill Medical 1996
    Google Scholar
  • 45 Dawson-Saunders B, Trapp R G. Bioestadíca Médica. 2nd ed. Mexico; Edit El Manual Moderno 1997
    Google Scholar
  • 46 Martínez-González M T, Vázquez C JL, Gallardo M G. Effectiveness of the BCG vaccine to prevent severe extra pulmonary Tb in children.  Int Pediatr. 2002;  17 110-114
    PubMedGoogle Scholar
  • 47 Menzies R, Visandjee B. Effect of bacilli Calmette-Guérin vaccination on tuberculin reactivity.  Am Rev Respir Dis. 1992;  145 621-625
    PubMedGoogle Scholar
  • 48 U.S. Preventive Services Task Force Committee .Screening for tuberculosis infection-including Bacillus Calmette-Guérin immunization. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD; Williams & Wilkins 1996: 277-286
    Google Scholar
  • 49 Rani H S, Vijayalakshmi V, Kumar S, Kiran A L, Suman L G, Murthy K JR. Cell mediated immunity in children with scar failure following BCG vaccination.  Indian Pediatr. 1998;  35 123-127
    PubMedGoogle Scholar
  • 50 Valenzuela N T, Ferrer X, Leal I, Pacheco M, Castillo N, Cumsille F. Comparative study of the efficacy of two types of BCG vaccines administered in different doses.  Rev Med Chil. 1998;  126 1126-1131
    PubMedGoogle Scholar
  • 51 Marchant A, Goetghebuer T, Ota M O et al.. Newborns develop a Th1-Type immune response to Mycobacterium bovis Bacillus Calmette-Guérin Vaccination.  J Immunol. 1999;  163 2249-2255
    PubMedGoogle Scholar
  • 52 Jiao X, Lo-Man R, Guermonprez P et al.. Dendritic cells are host cells for Mycobacteria in vivo that trigger innate and acquired immunity.  J Immunol. 2002;  168 1294-1301
    PubMedGoogle Scholar
  • 53 Ota M O, Vekemans J, Schlegel-Hauter S E et al.. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination.  J Immunol. 2002;  168 919-925
    PubMedGoogle Scholar
  • 54 Hussey G D, Watkins M L, Goddard E et al.. Neonatal mycobacterial specific cytotoxic T-lymphocyte an cytokine profiles in response to distinct BCG vaccination strategies.  Immunology. 2002;  105 314-324
    CrossrefPubMedGoogle Scholar
  • 55 Siegrist C A. Neonatal and early life vaccinology. Review.  Vaccine. 2001;  19 3931-3946
    PubMedGoogle Scholar
  • 56 Kovarik J, Siegrist C A. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators (Special feature: Immunological adjuvants).  Immunol Cell Biol. 1998;  76 222-236
    CrossrefPubMedGoogle Scholar
  • 57 Kröger L, Brander E, Korppi M et al.. Osteitis after newborn vaccination with three different Bacillus Calmette-Guérin vaccines: twenty-nine years of experience.  Pediatr Infect Dis. 1994;  12 113-116
    PubMedGoogle Scholar
  • 58 Peter G, Hall C B, Halsey N A, Marcy S M, Pickering L K, Orenstein N A. Tuberculosis. In: Red Book. Enfermedades Infecciosas en Pediatría. 24th ed. Buenos Aires, Argentina; Edit Panamericana 1999: 565-589
    Google Scholar

Lidia Negrete-EsquedaM.D. Sc.M. 

Montreal 225, Col. Villa Verde, León Gto.

México, 37281

      >